ArticleNAR genomics and bioinformatics2025
VIRUS-MVP: a framework for comprehensive surveillance of viral mutations and their functional impacts.
Article in NAR genomics and bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Mpox contextual data specification package: a data curation toolkit to support collaborative pathogen genomic surveillance.Microbial genomics · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As viruses evolve, they accumulate genetic mutations that can influence disease severity, transmissibility, and the effectiveness of vaccines and therapeutics. Real-time tracking of viral mutations and their functional impacts is essential to understand these changes and assess their implications for public health responses. VIRUS-MVP is an interactive, portable platform designed for the comprehensive surveillance of viral mutations. Initially developed for SARS-CoV-2, it now fully supports mpox and is expanding to include influenza and RSV. The platform links viral mutations to functional annotations, providing insights into their predicted effects on viral infectivity, immune evasion, and protein functionality. It features an interactive interface for visualizing mutation distributions, a modular and reproducible genomics workflow, and a curated annotation resource that captures known impacts on viral proteins and host interactions. Users can also import custom functional annotations to tailor analyses to specific research needs or emerging pathogens. Developed collaboratively with public health and academic partners, VIRUS-MVP enhances understanding of viral evolution and its public health impact by bridging genomic data with biological insights. The platform is open-source, adaptable, and accessible on GitHub.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.